Searching for "advisory" found 4

Rémy Levastre – Director of Healthcare Advisory Services, WSP Middle East

UAE Rémy Levastre – Director of Healthcare Advisory Services, WSP Middle East

UAE Rémy Levastre leads professional services firm WSP’s healthcare advisory services in the Middle East. Drawing on a diverse set of professional experiences, Levastre evaluates the influx and impact of cutting-edge digital tools into healthcare in his region, the opportunities and barriers to creating excellence in Middle East healthcare, and WSP’s…

Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020, what it means for that Aducanumab, and the impact on next-generation AD treatments. November 6 could prove to be…

Baltasar Lobato – Partner Advisory, Health & Life Sciences, EY Spain

Spain Baltasar Lobato – Partner Advisory, Health & Life Sciences, EY Spain

Spain Baltasar Lobato, managing partner of health and life sciences at EY Spain, highlights the major market trends affecting the public and private healthcare sector as well as the pharmaceutical market. He also gives an overview of the complex nature of the Spanish market, the importance of IT in creating a…

Pharmaceutical Benefits Advisory Committee Interview with Suzanne Hill, Chair, Pharmaceutical Benefits Advisory Committee

Pharmaceutical Benefits Advisory Committee To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the Ministry of Health and Ageing as to what drugs will be listed on the Pharmaceutical Benefits Scheme (PBS). The Minister…